Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit

(2018) Wiebren A.A. Tjalma et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study

(2018) Kyung Hae Jung et al.   ONCOLOGIST

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study

(2017) X. Pivot et al.   EUROPEAN JOURNAL OF CANCER

Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study

(2017) X. Pivot et al.   EUROPEAN JOURNAL OF CANCER

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

(2017) J. Gligorov et al.   EUROPEAN JOURNAL OF CANCER

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

(2017) David Cameron et al.   LANCET

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer

(2016) Erwin De Cock et al.   Cancer Medicine

Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study

(2015) L. Fallowfield et al.   BREAST

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study

(2014) C. Jackisch et al.   ANNALS OF ONCOLOGY

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

(2013) Xavier Pivot et al.   LANCET ONCOLOGY

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

(2012) Gustavo Ismael et al.   LANCET ONCOLOGY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Home care—a safe and attractive alternative to inpatient administration of intensive chemotherapies

(2011) François Lüthi et al.   SUPPORTIVE CARE IN CANCER

Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes

(2010) Mary Jo Lund et al.   CANCER

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST